Can Vertex Make Billions With a New Game-Changing Treatment? The Answer May Be Just Ahead
Vertex Pharmaceuticals (NASDAQ: VRTX) brings in billions of dollars in annual profit and revenue from its four cystic fibrosis (CF) treatments. The company is doing so well that, during this week's earnings report, it increased its annual revenue forecast -- again.
That sounds like great news. But Vertex had some even better news to report. And this news may ease investors' biggest worry about the biotech company. Since two non-CF candidates failed in clinical trials over the past year, investors have worried Vertex may struggle to expand beyond that therapeutic area. Vertex shares have tumbled about 30% since last October.
But Vertex may be ready to prove its ability to tackle other treatment areas. The company's CEO says a new game-changing treatment might be only a year away. Let's take a closer look.
Source Fool.com
